CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company’s egg precursor cell (EggPCSM ) technology platform will be featured in several presentations regarding female fertility preservation at the Society for Gynecologic Investigation (SGI) Summit Jerusalem 2013. This year’s SGI Summit, “From Implantation to Parturition”, New Frontiers in Women’s Health, is being held in Israel on May 28-30, 2013.
OvaScience Co-Founder Jonathan L. Tilly, Ph.D., a Massachusetts General Hospital-based Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Affiliated Faculty Member of the Harvard Stem Cell Institute in Boston, will report findings from his research that provide additional support for OvaScience’s patented technology and the Company’s AUGMENTSM and OvaTure SM product candidates.
Evelyn Telfer, Ph.D., of the Institute of Cell Biology and Centre for Integrative Physiology of the University of Edinburgh, will also report findings on her research on the generation of mature human eggs from human egg precursor cells.
Dr. Tilly commented, “The SGI summit provides an excellent platform for sharing our research on EggPCs and fertility with the global reproductive health community. It is particularly exciting to show promising results that may offer new hope for preserving fertility in women who have been diagnosed with cancer and for enhancing fertility success in women undergoing assisted reproduction technologies, such as in vitro fertilization (IVF).”
SGI Presentation Summaries:
Female Fertility Preservation Through Anti-Apoptotic Small Molecules
and Regenerative Medicine. Dr. Tilly will present scientific
findings from his laboratory demonstrating that damage to the ovaries
caused by exposure to cancer treatments, which often results in
infertility, can be minimized by several approaches, including
technologies involving EggPCs.
Fertility Preservation session: Wednesday, May 29, 12:00 p.m.
Round Table: Do Oogonial Stem Cells have Any Clinical Relevance? Drs.
Tilly and Telfer will participate in a discussion on how EggPCs can be
used to develop new treatment options for female infertility.
Wednesday, May 29, 2:20 p.m.
Defining the Significance of Female Germline Stem Cells to Ovarian
Development, Function and Failure. Dr. Tilly will describe new
results from his laboratory that further highlight the importance of
EggPCs to adult ovarian function, and will overview the science behind
the development of AUGMENTSM for improving IVF success.
Stem Cells in Reproduction session: Thursday, May 30, 10:20 a.m.
Can We Make New Human Oocytes from OSCs in Vitro? Dr. Telfer’s
lecture will review the current status of her research to generate
healthy, fertilizable human eggs from EggPCs entirely outside the body.
Stem Cells in Reproduction session: Thursday, May 30, 10:40 a.m.
OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com.
This press release includes forward-looking statements about the Company’s strategy, future plans and prospects, including statements regarding the development and planned launch of the Company’s product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.